Parabilis Medicines, Inc.
Every calculator, already run for PBLS
Open the full toolkit →You have the numbers on PBLS. Get the argument.
A written report on which of these readings actually decide the outcome for Parabilis Medicines, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
5 analysts covering PBLSAnalyst Price Target Disagreement for Parabilis Medicines, Inc.
Wall Street's bull case implies +11% from the current price; the bear case implies -1%. Analysts are relatively aligned on PBLS's range.
Ownership & short interest
Insider Trading Activity for PBLS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Parabilis Medicines, Inc.
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical…
PBLS — frequently asked
Is PBLS a buy right now?
Wall Street's consensus rating on Parabilis Medicines, Inc. is none across 5 analysts, with a mean price target of $41.75 (+3% vs. the current $40.42). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is PBLS's next earnings date?
Parabilis Medicines, Inc. is next scheduled to report earnings around Nov 12, 2026. A full PBLS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Parabilis Medicines, Inc.?
Analysts covering Parabilis Medicines, Inc. (PBLS) range from a bear-case target of $40.00 to a bull-case high of $45.00, with a mean consensus target of $41.75 across 4 analysts. The spread of $5.00 (12% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Parabilis Medicines, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Parabilis Medicines, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full PBLS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Parabilis Medicines, Inc., in minutes. 3 free reports included with every account — no credit card required.